Oncodrone gets EUR2.5m Eurostars grant to develop prostate cancer drug OCD155

The grant will allow the company to progress OCD155 through pre-clinical development towards clinical trials and to further unravel the mechanism-of-action, which will be done in a Dutch-Danish-German-Swiss consortium, including the Dutch partners Radboud UMC and Leiden UMC.

The company noted that OCD155 halts tumor progression by blocking Epethelial to Mesenchymal Transition (EMT) in cancers.

In in-vivo laboratory experiments, OCD155 has shown to be effective to reduce the ability of tumors to spread, reduce the tumor burden and treat advanced stages of disease.

After securing approval to be safe to use, the drug can be tested in patients with metastasized carcinoma’s including prostate, breast, lung and pancreatic cancer.

Eurostars supports international projects led by research and development- performing small- and medium-sized enterprises (R&D-performing SMEs).

It is joint program between Eureka and the European Commission, co-funded from the national budgets of 34 Eurostars Participating States and Partner Countries and by the EU through Horizon 2020.